Open AccessCardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
Author(s) -
Won Kyeong Jeon,
Jeehoon Kang,
Hyo Soo Kim,
Kyung Woo Park
Publication year - 2021
Publication title -
journal of lipid and atherosclerosis
Language(s) - English
Resource type - Journals
eISSN - 2288-2561
pISSN - 2287-2892
DOI - 10.12997/jla.2021.10.2.210
Subject(s) - medicine , metformin , mace , relative risk , myocardial infarction , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , type 2 diabetes mellitus , diabetes mellitus , meta analysis , sulfonylurea , stroke (engine) , heart failure , sitagliptin , lower risk , randomized controlled trial , clinical endpoint , confidence interval , endocrinology , insulin , percutaneous coronary intervention , mechanical engineering , engineering
Recent studies have raised concern about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review through meta-analysis to compare cardiovascular outcomes of sulfonylurea (SU) versus DPP4 inhibitors when used in combination with metformin.